Michelle Freyre - Estee Lauder Insider
| EL Stock | USD 69.16 2.32 3.47% |
Insider
Michelle Freyre is Senior Vice President Global General Manager - Clinique of Estee Lauder Companies since 2021.
| Tenure | 3 years |
| Address | 767 Fifth Avenue, New York, NY, United States, 10153 |
| Phone | 212 572 4200 |
| Web | https://www.elcompanies.com |
Estee Lauder Management Efficiency
The company has Return on Asset (ROA) of 0.0457 % which means that for every $100 of assets, it generated a profit of $0.0457. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.0386 %, which means that it produced $0.0386 on every 100 dollars invested by current stockholders. Estee Lauder's management efficiency ratios could be used to measure how well Estee Lauder manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to 0.03. The value of Return On Capital Employed is expected to slide to 0.06. At this time, Estee Lauder's Total Assets are quite stable compared to the past year. Non Current Assets Total is expected to rise to about 14.4 B this year, although the value of Other Current Assets will most likely fall to about 448.4 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Aliza Scott | FormFactor | N/A | |
| Ioannis Aloukos | Aegean Airlines SA | N/A | |
| BCom LLM | Gold Fields Ltd | 44 | |
| Michael Kouveliotis | Aegean Airlines SA | N/A | |
| Pehlevanoudis Zisis | Aegean Airlines SA | N/A | |
| Rosh Bardien | Gold Fields Ltd | 48 | |
| Iosif Mastorantonakis | Aegean Airlines SA | N/A | |
| John Barrett | Adams Resources Energy | 86 | |
| Michael Fleming | Merck Company | 61 | |
| Stuart Mathews | Gold Fields Ltd | 59 | |
| Risa LavizzoMourey | Merck Company | 66 | |
| Msc MSc | Gold Fields Ltd | 59 | |
| Robert Waltermire | Madrigal Pharmaceuticals | 60 | |
| Dean Li | Merck Company | 58 | |
| Jannie Oosthuizen | Merck Company | 53 | |
| Steven Nott | FormFactor | N/A | |
| Wanda Fearing | Cinemark Holdings | 60 | |
| Deepak Khanna | Merck Company | N/A | |
| Caren Bedard | Cinemark Holdings | N/A | |
| Paul MD | Madrigal Pharmaceuticals | 81 | |
| Arpa Garay | Merck Company | 42 | |
Management Performance
| Return On Equity | 0.0386 | ||||
| Return On Asset | 0.0457 |
Estee Lauder Companies Leadership Team
Elected by the shareholders, the Estee Lauder's board of directors comprises two types of representatives: Estee Lauder inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Estee. The board's role is to monitor Estee Lauder's management team and ensure that shareholders' interests are well served. Estee Lauder's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Estee Lauder's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tracey Travis, CFO, Principal Accounting Officer and Executive VP | ||
| Andrew Ross, Senior Vice President - Strategy and New Business Development | ||
| Nicole Monson, Senior Vice President - Equity and Engagement (Lead COE) | ||
| Mark Loomis, President - North America | ||
| Wei Christianson, Independent Director | ||
| John Demsey, Executive Group President | ||
| Akhil Shrivastava, Former Controller | ||
| Rashida Lande, Executive Counsel | ||
| Michael OHare, Executive Vice President - Global Human Resources | ||
| Carl Haney, Executive Vice President - Global Research and Development, Corporate Product Innovation, Package Development | ||
| Laraine Mancini, Senior Relations | ||
| Jane Lauder, Executive Vice President - Enterprise Marketing and Chief Data Officer, Director | ||
| Richard Parsons, Director | ||
| William Lauder, Executive Chairman and Member of Nominating and Board Affairs Committee | ||
| Gregory Polcer, Executive Vice President - Global Supply Chain | ||
| Barry Sternlicht, Independent Director | ||
| Ronald Lauder, Chairman of Clinique Laboratories, LLC, Director | ||
| Rose Bravo, Independent Director | ||
| Meridith Webster, Executive Vice President Global Communications and Public Affairs | ||
| Fabrizio Freda, President, Chief Executive Officer, Director | ||
| Marc Prouve, Group President - International | ||
| Glenn Evans, President - Global Brand, Smashbox and Glamglow | ||
| Alexandra Trower, Executive Vice President - Global Communications | ||
| Jennifer Tejada, Independent Director | ||
| Jane Hudis, Executive Group President | ||
| Joy Fan, President, Chief Executive Officer. China | ||
| Leonard Lauder, Chairman Emeritus | ||
| Deirdre Stanley, Executive Vice President General Counsel | ||
| Charlene Barshefsky, Presiding Independent Director | ||
| Sara Moss, Executive Vice President General Counsel | ||
| Roberto Canevari, Executive Vice President - Global Supply Chain | ||
| Richard Zannino, Independent Director | ||
| Paul Fribourg, Independent Director | ||
| Peter Jueptner, President - Europe, the Middle East and Africa | ||
| Deirdre Esq, Executive Counsel | ||
| Lynn Rothschild, Independent Director | ||
| Stephane Faverie, Global Brand President - Origins and Darphin | ||
| Cedric Prouve, Group President of International | ||
| Irvine Hockaday, Presiding Independent Director | ||
| Michelle Freyre, Senior Vice President Global General Manager - Clinique | ||
| Jennifer Hyman, Independent Director | ||
| Deborah Krulewitch, Senior Administration |
Estee Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Estee Lauder a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0386 | ||||
| Return On Asset | 0.0457 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.04 % | ||||
| Current Valuation | 31.11 B | ||||
| Shares Outstanding | 233.44 M | ||||
| Shares Owned By Insiders | 0.43 % | ||||
| Shares Owned By Institutions | 89.97 % | ||||
| Number Of Shares Shorted | 5.05 M | ||||
| Price To Earning | 36.55 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Estee Lauder Companies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Personal Care Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Estee Lauder. If investors know Estee will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Estee Lauder listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.116 | Dividend Share 2.64 | Earnings Share 0.56 | Revenue Per Share 43.003 | Quarterly Revenue Growth (0.04) |
The market value of Estee Lauder Companies is measured differently than its book value, which is the value of Estee that is recorded on the company's balance sheet. Investors also form their own opinion of Estee Lauder's value that differs from its market value or its book value, called intrinsic value, which is Estee Lauder's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Estee Lauder's market value can be influenced by many factors that don't directly affect Estee Lauder's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Estee Lauder's value and its price as these two are different measures arrived at by different means. Investors typically determine if Estee Lauder is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Estee Lauder's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.